On March 17, 2025, Valcare Medical announced exciting news: The U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE).Officially Launch Early Feasibility Study (EFS) for Amend Transseptal System. This approval is not only a critical milestone in the development journey of Valcare Medical but also heralds a new transformation in the field of mitral regurgitation treatment.

Revolutionary Amend Transseptal System

Amend Transseptal System, as a transcatheter device, is highly innovative in its design. It employs a semi-rigid, closed D-shaped annuloplasty ring, aiming to mimic the current surgical gold standard for treating mitral regurgitation. Mitral regurgitation is a common and serious heart condition that affects the quality of life and health of many patients. Traditional treatment methods have certain limitations, while the Amend Transseptal System is expected to break this situation and bring new hope to patients.

EFS Research Details

This EFS study is of great significance, primarily focusing on evaluating the safety and functionality of the Amend transseptal system in a specific patient population.The study population consisted of patients with symptomatic moderate-to-severe (3+) or severe (4+) functional mitral regurgitation (FMR) who were anatomically suitable for transcatheter mitral annuloplasty.The study will be conducted across seven research centers in the United States, with plans to recruit up to 15 participants. Patient treatment is expected to commence in the first half of 2025, laying a solid foundation for pivotal studies in 2027.

The primary and secondary endpoints of the study cover multiple aspects. Safety and device performance evaluation are the main focus, including technical success in annuloplasty delivery, implantation, and retrieval of the delivery system. Relevant patient outcomes such as stroke, myocardial infarction (MI), non-elective cardiovascular surgeries due to device-related complications, and all-cause mortality need to be reported in detail at 30 days and 6 months post-implantation. Additionally, changes in New York Heart Association (NYHA) functional class, 6-minute walk test results, quality of life at 30 days and 6 months, and a reduction of at least one grade in mitral regurgitation (MR) severity from baseline at 30 days, 6 months, and 1 year are included as part of the secondary endpoints.

Expert Opinion

AMEND EFS Study Chair Scott Lim from the University of Virginia, Charlottesville, stated: "I am very excited and eager to initiate the AMEND Transseptal System EFS to further evaluate this highly promising new technology. The AMEND Annuloplasty Ring has the potential to improve mitral valve repair outcomes for patients who are considered unsuitable for existing therapies. Additionally, the AMEND system offers a minimally invasive alternative to the gold standard surgical repair, and I am highly optimistic about its potential in treating patients with severe mitral regurgitation."

Steve Sandweg, President and CEO of Valcare Medical, also enthusiastically stated, "The FDA approval to initiate the revised EFS is a significant milestone for Valcare Medical on the path to final pre-market approval in the United States. I am incredibly proud of the entire Valcare Medical team for achieving this major accomplishment."

This FDA approval to initiate the EFS undoubtedly injects strong momentum into Valcare Medical's development. As the research progresses gradually, the Amend transseptal system is expected to provide patients with mitral regurgitation a more effective and safer treatment option in the future. Let us jointly look forward to this medical innovation benefiting more patients as soon as possible.